ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.+24.7%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ARQT vs DERM vs SKIN vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
DERM
Journey Medical Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$102M
5Y Perf.-36.8%
SKIN
The Beauty Health Company
Household & Personal Products
Market Cap$118M
5Y Perf.-96.5%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-82.0%
ARQT vs DERM vs SKIN vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ARQT | DERM | SKIN | NVCR |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Household & Personal Products | Medical - Instruments & Supplies |
| Market Cap | $2.58B | $102M | $118M | $1.92B |
| Revenue (TTM) | $416M | $56M | $296M | $674M |
| Net Income (TTM) | $-2M | $-9M | $-6M | $-173M |
| Gross Margin | 90.9% | 67.5% | 64.9% | 75.2% |
| Operating Margin | 0.8% | -12.2% | -3.6% | -27.2% |
| Forward P/E | 77.6x | 69.0x | — | — |
| Total Debt | $6M | $26M | $379M | $290M |
| Cash & Equiv. | $43M | $20M | $233M | $103M |
ARQT vs DERM vs SKIN vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ARQT
DERM
SKIN
NVCR
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Arcutis Biotherapeu… (ARQT) | 100 | 124.7 | +24.7% |
| Journey Medical Cor… (DERM) | 100 | 63.2 | -36.8% |
| The Beauty Health C… (SKIN) | 100 | 3.5 | -96.5% |
| NovoCure Limited (NVCR) | 100 | 18.0 | -82.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARQT vs DERM vs SKIN vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARQT leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Journey Medical Corporation is the stronger pick specifically for valuation and capital efficiency. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ARQT
Arcutis Biotherapeutics, Inc.
The Income Pick
ARQT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.48
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- -5.2% 10Y total return vs NVCR's 30.3%
- Lower volatility, beta 1.48, Low D/E 3.3%, current ratio 3.17x
Best for: income & stability and growth exposure
DERM
Journey Medical Corporation
The Value Play
DERM is the #2 pick in this set and the best alternative if value is your priority.
- Better valuation composite
Best for: value
SKIN
The Beauty Health Company
The Quality Angle
SKIN plays a supporting role in this comparison — it may shine differently against other peers.
Best for: consumer defensive exposure
NVCR
NovoCure Limited
The Secondary Option
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARQT | 91.3% revenue growth vs DERM's -29.1% |
| Value | DERM | Better valuation composite |
| Quality / Margins | ARQT | -0.6% margin vs NVCR's -25.7% |
| Stability / Safety | ARQT | Beta 1.48 vs NVCR's 2.20, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ARQT | +50.8% vs SKIN's -35.9% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs NVCR's -16.5%, ROIC -5.2% vs -16.4% |
ARQT vs DERM vs SKIN vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2024
FY 2025
Segment breakdown not available.
ARQT vs DERM vs SKIN vs NVCR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGNVCR
Who Leads Where
ARQT leads in 2 of 6 categories
SKIN leads 1 • DERM leads 0 • NVCR leads 0 • 2 tied
Explore the data ↓NVCRNovoCure Limited
0leads
DERMJourney Medical Corpo…
0leads
SKINThe Beauty Health Com…
1leads
ARQTArcutis Biotherapeuti…
2leads
6 Total Categories
CATEGORYLEADERvs SKINvs DERMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT5/6
Valuation MetricsMultiples, price ratios, and targets
SKIN2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 12.0x DERM's $56M. ARQT is the more profitable business, keeping -0.6% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ARQT holds the edge at +60.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARQTArcutis Biotherap… | DERMJourney Medical C… | SKINThe Beauty Health… | NVCRNovoCure Limited |
|---|---|---|---|---|
| RevenueTrailing 12 months | $416M | $56M | $296M | $674M |
| EBITDAEarnings before interest/tax | $6M | -$3M | $9M | -$165M |
| Net IncomeAfter-tax profit | -$2M | -$9M | -$6M | -$173M |
| Free Cash FlowCash after capex | $27M | -$3M | $29M | -$48M |
| Gross MarginGross profit ÷ Revenue | +90.9% | +67.5% | +64.9% | +75.2% |
| Operating MarginEBIT ÷ Revenue | +0.8% | -12.2% | -3.6% | -27.2% |
| Net MarginNet income ÷ Revenue | -0.6% | -15.5% | -2.0% | -25.7% |
| FCF MarginFCF ÷ Revenue | +6.5% | -4.8% | +9.8% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +60.1% | +1.0% | -6.7% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +55.0% | +5.9% | +38.0% | -100.0% |
ARQT leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
SKIN leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | ARQTArcutis Biotherap… | DERMJourney Medical C… | SKINThe Beauty Health… | NVCRNovoCure Limited |
|---|---|---|---|---|
| Market CapShares × price | $2.6B | $102M | $118M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $108M | $264M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -158.92x | -6.94x | -5.69x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 77.64x | 68.97x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 7331.15x | — |
| Price / SalesMarket cap ÷ Revenue | 6.87x | 1.82x | 0.39x | 2.92x |
| Price / BookPrice ÷ Book value/share | 13.87x | 5.09x | 2.02x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — | 3.17x | — |
SKIN leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-51 for NVCR. ARQT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs DERM's 2/9, reflecting strong financial health.
| Metric | ARQTArcutis Biotherap… | DERMJourney Medical C… | SKINThe Beauty Health… | NVCRNovoCure Limited |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -1.4% | -45.4% | -9.4% | -50.8% |
| ROA (TTM)Return on assets | -0.6% | -10.8% | -1.2% | -16.5% |
| ROICReturn on invested capital | -5.2% | -56.8% | -6.8% | -16.4% |
| ROCEReturn on capital employed | -4.3% | -34.2% | -4.5% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.03x | 1.28x | 6.20x | 0.85x |
| Net DebtTotal debt minus cash | -$37M | $5M | $146M | $187M |
| Cash & Equiv.Liquid assets | $43M | $20M | $233M | $103M |
| Total DebtShort + long-term debt | $6M | $26M | $379M | $290M |
| Interest CoverageEBIT ÷ Interest expense | 2.08x | -1.52x | 0.81x | -96.80x |
ARQT leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ARQT and DERM and NVCR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARQT five years ago would be worth $6,053 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, ARQT leads with a +50.8% total return vs SKIN's -35.9%. The 3-year compound annual growth rate (CAGR) favors DERM at 44.7% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | ARQTArcutis Biotherap… | DERMJourney Medical C… | SKINThe Beauty Health… | NVCRNovoCure Limited |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -28.8% | -32.9% | -35.0% | +28.3% |
| 1-Year ReturnPast 12 months | +50.8% | -28.1% | -35.9% | +1.1% |
| 3-Year ReturnCumulative with dividends | +44.9% | +203.0% | -91.7% | -75.7% |
| 5-Year ReturnCumulative with dividends | -39.5% | -47.4% | -92.9% | -91.3% |
| 10-Year ReturnCumulative with dividends | -5.2% | -47.4% | -91.6% | +30.3% |
| CAGR (3Y)Annualised 3-year return | +13.2% | +44.7% | -56.4% | -37.6% |
Evenly matched — ARQT and DERM and NVCR each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ARQT and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARQT is the less volatile stock with a 1.48 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs SKIN's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARQTArcutis Biotherap… | DERMJourney Medical C… | SKINThe Beauty Health… | NVCRNovoCure Limited |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.48x | 1.82x | 2.00x | 2.20x |
| 52-Week HighHighest price in past year | $31.77 | $9.55 | $2.69 | $20.06 |
| 52-Week LowLowest price in past year | $12.42 | $4.31 | $0.76 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +52.3% | +33.8% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 54.3 | 44.3 | 52.1 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 230K | 760K | 1.5M |
Evenly matched — ARQT and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ARQT as "Buy", DERM as "Buy", SKIN as "Hold", NVCR as "Buy". Consensus price targets imply 135.0% upside for DERM (target: $12) vs 42.9% for SKIN (target: $1).
| Metric | ARQTArcutis Biotherap… | DERMJourney Medical C… | SKINThe Beauty Health… | NVCRNovoCure Limited |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $35.50 | $11.75 | $1.30 | $33.50 |
| # AnalystsCovering analysts | 12 | 3 | 13 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SKIN leads in 1 (Valuation Metrics). 2 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 2 of 6 categories
Loading custom metrics...
ARQT vs DERM vs SKIN vs NVCR: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ARQT or DERM or SKIN or NVCR a better buy right now?
For growth investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Arcutis Biotherapeutics, Inc. (ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARQT or DERM or SKIN or NVCR?
Over the past 5 years, Arcutis Biotherapeutics, Inc.
(ARQT) delivered a total return of -39. 5%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARQT or DERM or SKIN or NVCR?
By beta (market sensitivity over 5 years), Arcutis Biotherapeutics, Inc.
(ARQT) is the lower-risk stock at 1. 48β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 49% more volatile than ARQT relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — ARQT or DERM or SKIN or NVCR?
By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.
(ARQT) is pulling ahead at 91. 3% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ARQT or DERM or SKIN or NVCR?
The Beauty Health Company (SKIN) is the more profitable company, earning -3.
2% net margin versus -26. 1% for Journey Medical Corporation — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARQT leads at -3. 3% versus -24. 4% for DERM. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ARQT or DERM or SKIN or NVCR more undervalued right now?
On forward earnings alone, Journey Medical Corporation (DERM) trades at 69.
0x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.
07Which pays a better dividend — ARQT or DERM or SKIN or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ARQT or DERM or SKIN or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARQT: -5. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ARQT and DERM and SKIN and NVCR?
These companies operate in different sectors (ARQT (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ARQT is a small-cap high-growth stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ARQT: 60.1% · DERM: 1.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.